Assessment of in silico models for fraction of unbound drug in human liver microsomes

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 5, 2010, Pages 533-542

  Gao, Hua ^a   Steyn, Stefanus J ^a   Chang, George ^a   Lin, Jing ^a  

^a PFIZER INC   (United States)

Author keywords

Fraction of unbound drug in human liver microsomes; In silico model; Microsomal binding; QSAR; QSPR

Indexed keywords

CYTOCHROME P450;

ACCURACY; COMPUTER MODEL; DRUG BINDING; DRUG CLEARANCE; HYDROGEN BOND; IC 50; LINEAR REGRESSION ANALYSIS; LIPOPHILICITY; LIVER MICROSOME; METHODOLOGY; MICROSOME; PHARMACOPHORE; PHYSICAL CHEMISTRY; PROTEIN BINDING; REVIEW;

COMPUTER SIMULATION; DRUG DESIGN; HUMANS; HYDROGEN BONDING; MICROSOMES, LIVER; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING;

EID: 77951261774     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425251003671022     Document Type: Review

References (59)

1. Lipinski CA. Drug-Like Properties and the Causes of Poor Solubility and Poor Permeability. J Pharmacol Toxicol Methods 2000;44:235-249
2. Clark DE, Pickett SD. Computational methods for the prediction of "Drug-Likeness". Drug Discov Today 2000;5:49-58
3. Walters WP. Murcko MA. Prediction of "Drug-Likeness". Adv Drug Delivery Rev 2002;54:255-271
4. Lin J, Sahakian DC, de Morais SM, et al. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem 2003;3:1125-1154
5. Wagner JG, Northam JI, Alway CD, Carpenter OS. Blood levels of drug at the equilibrium state after multiple dosing. Nature 1968;207:1301-1302
6. Gao H, Yao Y, Mathieu HW, et al. In silico modeling of nonspecific binding to human liver microsomes. Drug Metab Dispos 2008;36:2130-2135
7. Gillette J. Drug metabolism by enzyme mechanisms. Prog Drug Res 1963;6:55-57
8. Kalvass JC, Tess DA, Giragossian C, et al. Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data. Drug Metab Dispos 2001;29:1332-1336 (Pubitemid 32896583)
9. Margolis JM, Obach RS. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 2003;31:606-611
10. Obach RS. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 1997;25:1359-1369
11. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999;27:1350-1359
12. Tran TH, Von Moltke LL, Venkatakrishnan K, et al. Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 2002;30:1441-1445 (Pubitemid 35397052)
13. Obach RS. The importance of nonspecific binding in vitro matrixes, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metab Dispos 1996;24:1047-1049
14. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815-832
15. Grime K, Riley RJ. The impact of in vitro binding on in vitro -- in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr Drug Metab 2006;7:251-264
16. Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--toward a consensus. Pharm Res 2001;18:1071-1080 (Pubitemid 32900389)
17. Li H, Sun J, Sui X, et al. Structure-based prediction of the nonspecific binding of drugs to hepatic microsomes. AAPS J 2009;11:364-370
18. Banker MJ, Clark TH, Williams JA. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 2003;92:967-974
19. Giuliano C, Jairaj M, Zafiu CM, Laufer R. Direct determination of unbound intrinsic drug clearance in the microsomal stability assay. Drug Metab Dispos 2005;33:1319-1324 (Pubitemid 41196974)
20. Nakai D, Kumamoto K, Sakikawa C, et al. Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method. J Pharm Sci 2004;93(4):847-854 (Pubitemid 38420397)
21. Gao H, Shanmugasundaram V, Lee P. Estimation of aqueous solubility of organic compounds with QSPR approach. Pharm Res 2002;19(4):497-503 (Pubitemid 34408951)
22. Selassie CD, DeSoyza TV, Rosario M, et al. Phenol toxicity in leukemia cells: a radical process? Chem Biol Interact 1998;113(3):175-190 (Pubitemid 28274539)
23. Koneru PB, Lien EJ, Koda RT. Oculotoxicities of systemically administered drugs. J Ocul Pharmacol 1986;2(4):385-404
24. Ren S, Lien EJ. Caco-2 cell permeability vs human gastrointestinal absorption: QSPR analysis. Prog Drug Res 2000;54:1-23 (Pubitemid 30311719)
25. Lien EJ, Gao H. QSAR analysis of skin permeability of various drugs in man as compared to in vivo and in vitro studies in rodents. Pharm Res 1995;12(4):583-587
26. Lien EJ. Structure-activity relationships and drug disposition. Ann Rev Pharmacol Toxicol 1981;21:31-61
27. Lien EJ. Structure, properties and disposition of drugs. Prog Drug Res 1985;29:67-95
28. Giaginis C, Zira A, Theocharis S, Tsantili-Kakoulidou A. Application of quantitative structure-activity relationships for modeling drug and chemical transport across the human placenta barrier: a multivariate data analysis approach. J Appl Toxicol 2009;29(8):724-733
29. Gao H, Hansch C. QSAR of p450 oxidation: on the value of comparing kcat and km with kcat/km. Drug Metab Rev 1996;28(4):513-526 (Pubitemid 26417561)
30. Ren S, Das A, Lien EJ. QSAR analysis of membrane permeability to organic compounds. J Drug Target 1996;4(2):103-107 (Pubitemid 26381472)
31. Li H, Sun J, Sui X, et al. First-principle, structure-based prediction of hepatic metabolic clearance values in human. Eur J Med Chem 2009;44(4):1600-1606
32. Nikolic K, Agababa D. Prediction of hepatic microsomal intrinsic clearance and human clearance values of drugs. J Mol Graph Model 2009;28(3):245-252
33. Lee PH, Cucurull-Sanchez L, Lu J, Du YJ. Development of in silico models for human liver microsomal stability. J Comput Aided Mol Des 2007; 21(12):665-673
34. Chen Y, Cameron K, Guzman-Perez A, et al. Structure-pharmacokinetic relationship of in vivo rat biliary excretion. Biopharm Drug Dispos
35. 2009. In press
36. Sun H, Scott DO. Structure-based drug metabolism predictions for drug design. Chem Biol Drug Des 2010;75(1):3-17
37. Fujita T, Hansch C. Analysis of the structure-activity relationship of the sulfonamide drugs using substituent constants. J Med Chem 1967;10(6):991-1000
38. Muir RM, Fujita T, Hansch C. Structure-activity relationship in the auxin activity of mono-substituted phenylacetic acids. Plant Physiol 1967;42(11):1519-1526
39. Iwasa J, Fujita T, Hansch C. Substituent constants for aliphatic functions obtained from partition coefficients. J Med Chem 1965; 8:150-153
40. Hansch C, Hoekman D, Gao H. Comparative QSAR: toward a deeper understanding of chemicobiological interactions. Chem Rev 1996;96(3):1045-1076 (Pubitemid 126641477)
41. Gao H, Katzenellenbogen JA, Garg R, Hansch C. Comparative QSAR analysis of estrogen receptor ligands. Chem Rev 1999;99(3):723-744
42. McLure JA, Miners JO, Birkett DJ. Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 2000;49(5):453-461 (Pubitemid 30229449)
43. Austin RP, Barton P, Cockroft SL, et al. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 2002;30(12):1497-1503 (Pubitemid 35397059)
44. Hallifax D, Houston JB. Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug. Metab. Dispos. 2006; 34(4):724-726
45. Turner DB, Rowland-Yeo K, Tucker GT, andRostami-Hodjegan A. Prediction of non-specific hepatic microsomal binding from readily available physicochemical properties. Drug Metab Rev 2006;38(Suppl 1):162
46. Sykes MJ, Sorich MG, Miners JO. Molecular modeling approaches for the prediction of the nonspecific binding of drugs to hepatic microsomes. J Chem Inf Model 2006;46(6):2661-2673
47. Kilford PJ, Gertz M, Houston JB, Galetin A. Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab Dispos 2008;36(7):1194-1197 (Pubitemid 351929330)
48. Gertz M, Kilford PJ, Houston JB, Galetin A. Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. DrugMetab Dispos 2008;36(3):535-542 (Pubitemid 351397979)
49. Austin RP, Davis AM, Manners CN. Partitioning of ionizing molecules between aqueous buffers and phospholipid vesicles. J Pharm Sci 1995;84:1180-1183
50. Krämer SD, Braun A, Jakits-Deiser C, Wunderli-Allenspach H. Towards the predictability of drug-lipid membrane interactions: the pH-dependent affinity of propranolol to phosphatidylinositol containing liposomes. Pharm Res 1998;15:739-744 (Pubitemid 28275651)
51. Austin RP, Barton P, Riley RJ. Response to "Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement". Drug Metab Dispos 2006;34(4):727
52. Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: impact of plasma and microsomal binding. Xenobiotica 2009;393:227-235
53. ROCS, version 2.1.1. Openeye Scientific Software. Santa Fe, NM; 2005.
54. Rulequest Research. 2006. Available from: www.rulequest.com
55. De Buck SS, Sinha VK, Fenu LA, et al. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos 2007;35:649-659
56. FagerholmU. Prediction of human pharmacokinetics -- evaluation of methods for prediction of hepatic metabolic clearance. J Pharm Pharmacol 2007;59:803-828 (Pubitemid 47051093)
57. Barre J, Chamouard JM, Houin G, Tlllement JP. Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid. Clin Chem 1985;31(1):60-64 (Pubitemid 15079346)
58. Gleeson MP. Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis. J Med Chem 2007;50:101-112
59. Zhang Y, Yao L, Lin J, et al. Lack of appreciable species differences in nonspecific microsomal binding. J Pharm Sci 2010. In press